Advanced first-in-class, one-day oral antifungal treatment, BREXAFEMME is now covered for approximately 55 percent of…
CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans…
WALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) today announced its participation…
SOMERVILLE, Mass., April 19, 2022 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch…
Dr. El-Gabry’s extensive leadership experience will be critical to accelerating Akoya’s groundbreaking spatial biomarker research…
Expects to Report Results of Independent Data Monitoring Committee (IDMC) Mandated Interim Safety Reviews and…
Accomplished business executive and attorney with diverse industry experience including over 20 years in life…
Biotech executive with robust experience in financial and corporate strategy and operational excellence will strengthen…
– Strengthens intellectual property portfolio for macimorelin and the commercial product Ghryvelin®/ Macrilen™in Europe as…
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
MORRISVILLE, N.C., April 19, 2022 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated…
Company to begin hosting quarterly calls to provide broad updates across pipeline WATERTOWN, Mass., April…
Results of “SPEED” study confirm the speed of diagnostic effectiveness of a single microdose array…
FLORHAM PARK, N.J., April 19, 2022 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB), a…
Niclosamide Inhalation Powder Well Tolerated with No Serious Adverse Events Across All Subject Cohorts Current…
Approval adds HPV to menu of tests available on Enzo’s GenFlex® platform, which includes COVID-19…
Three ASCRS presentations will feature data from Nyxol® clinical studies: second Phase 3 MIRA-3 trial…
PRINCETON, N.J., April 19, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a…
GCC19CART is an autologous CAR T therapy candidate that has shown promising results in over…